VJHemOnc is committed to improving our service to you

EHA 2016 | Treating pediatric ALL with chimeric antigen receptor (CAR) T-cell therapy

VJHemOnc is committed to improving our service to you

Stephan Grupp

Stephan Grupp, MD, PhD from Children’s Hospital of Philadelphia, Philadelphia, PA discusses his research into pediatric acute lymphoid leukemia (ALL). In a relapsed or refractory setting 93% of the patients entered complete remission (CR) when treated with CTL019, a chimeric antigen receptor T-cell (CAR T-cell). Furthermore, many of these patients were able to stay in remission. Dr Grupp also discussed toxicity associated with these engineered T-cell, specifically cytokine release syndrome. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter